Immune effectors required for the therapeutic activity of vorinostat.

摘要

Suberanilohydroxamic acid, a pan-histone deacetylase inhibitor (HDACi) best known as vorinostat (marketed under the name Zolinza? by Merck and Co., Inc.), was approved by the US Food and Drug Administration (FDA) for use in patients with cutaneous T-cell lymphoma (CTCL) in 2006. Similar to other targeted anticancer agents, vorinostat has been developed based on the assumption that it would mediate direct cytotoxic effects on malignant cells. Indeed, vorinostat has been shown to trigger the apoptotic demise of cancer cells in vivo, in syngeneic models of murine adenocarcinoma and lymphoma as well as in mice bearing human acute lymphoblastic leukemia.